Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Aripiprazole is a new antipsychotic agent approved for the treatment of schizophrenia. This atypical agent is a quinolinone that has partial agonist activity at dopamine D2 receptors. The drug will be marketed as being better tolerated and safer than other atypical agents, as well as being dosed once a day.

Pharmacology Update: Aripiprazole Tablets (Abilify — Bristol-Myers Squibb)